More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after CVS Health Corp. reversed a controversial decision to restrict it for certain drug plans.
The reversal comes after Lilly agreed to cut the price it charges many health plans for Zepbound, a spokesperson for CVS said. In July, CVS’s Caremark drug benefit unit, which negotiates medicine prices for insurance plans, began restricting access to Zepbound because of a deal with rival Novo Nordisk A/S that secured a better price for Wegovy.